Literature DB >> 23853563

Obstructive sleep apnea in patients with end-stage lung disease.

Ayal Romem1, Aldo Iacono, Elizabeth McIlmoyle, Kalpesh P Patel, Robert M Reed, Avelino C Verceles, Steven M Scharf.   

Abstract

OBJECTIVES: Little is known about the rate of obstructive sleep apnea (OSA) in patients with end stage lung disease (ESLD). Given the potential deleterious effect of OSA in these patients, we assessed the case-rate and severity of OSA and described associated patient characteristics.
METHODS: Retrospective survey of 60 patients with ESLD referred for lung transplantation evaluation. Demographic, polysomnographic, spirometric, and medication utilization data were extracted and analyzed.
RESULTS: As demographic and polysomnographic data did not differ between obstructive and restrictive patients, we present analysis of pooled data. Demographics/physiology: median age was 58.5 years, 52% males, mean BMI 32.3 kg/m(2), 52% obstructive. Sleep variables (all medians): total sleep time (TST) 312 min, sleep efficiency 77%, minimal oxygen saturation 84%, apnea hypopnea (AHI) 9.7, respiratory disturbance index (RDI) 12.7 events/h of sleep. Sixty-seven percent had RDI > 5; 21% had RDI between 15 and 30; and 21% had RDI > 30. Periodic limb movement index ≥ 15/h sleep was present in 21.7%. An independent positive correlation between DLCO% and RDI was noted (r = 0.41, p < 0.01). The minimal oxygen saturation was negatively correlated with the RDI (r = -0.34, p < 0.01). The use of ACE inhibitors was associated with moderate-to-severe OSA (odd ratio of 4.67, CI 1.45-15.03; p = 0.017).
CONCLUSIONS: In patients with ESLD, organic sleep disorders are common. Greater severity of OSA was associated with the higher DLCO% and lower oxygen saturation.

Entities:  

Mesh:

Year:  2013        PMID: 23853563      PMCID: PMC3671334          DOI: 10.5664/jcsm.2840

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  37 in total

Review 1.  Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force.

Authors: 
Journal:  Sleep       Date:  1999-08-01       Impact factor: 5.849

Review 2.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

3.  Prospective trial on obstructive sleep apnea in pregnancy and fetal heart rate monitoring.

Authors:  Sofia A Olivarez; Bani Maheshwari; Meghan McCarthy; Nikolaos Zacharias; Ignatia van den Veyver; Lata Casturi; Haleh Sangi-Haghpeykar; Kjersti Aagaard-Tillery
Journal:  Am J Obstet Gynecol       Date:  2010-02-20       Impact factor: 8.661

4.  Excess weight and sleep-disordered breathing.

Authors:  Terry Young; Paul E Peppard; Shahrad Taheri
Journal:  J Appl Physiol (1985)       Date:  2005-10

5.  Angiotensin-converting enzyme inhibitors and obstructive sleep apnea.

Authors:  Alessandro Cicolin; Lucia Mangiardi; Roberto Mutani; Caterina Bucca
Journal:  Mayo Clin Proc       Date:  2006-01       Impact factor: 7.616

6.  How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis?

Authors:  Charalampos Mermigkis; Eleni Stagaki; Stavros Tryfon; Sophia Schiza; Anastasia Amfilochiou; Vlassios Polychronopoulos; Panagiotis Panagou; Nikolaos Galanis; Anastasios Kallianos; Demetrios Mermigkis; Antony Kopanakis; Georgios Varouchakis; Fotis Kapsimalis; Demosthenis Bouros
Journal:  Sleep Breath       Date:  2010-03-16       Impact factor: 2.816

7.  The single-breath diffusing capacity for carbon monoxide in obstructive sleep apnea and obesity.

Authors:  P Collard; J Y Wilputte; G Aubert; D O Rodenstein; A Frans
Journal:  Chest       Date:  1996-11       Impact factor: 9.410

8.  Quality of life in obstructive sleep apnea: a systematic review of the literature.

Authors:  C A Moyer; S S Sonnad; S L Garetz; J I Helman; R D Chervin
Journal:  Sleep Med       Date:  2001-11       Impact factor: 3.492

9.  Polysomnographic respiratory abnormalities in asymptomatic individuals.

Authors:  Milena K Pavlova; Jeanne F Duffy; Steven A Shea
Journal:  Sleep       Date:  2008-02       Impact factor: 5.849

Review 10.  Obstructive sleep apnea, cardiovascular disease, and inflammation--is NF-kappaB the key?

Authors:  Antoinette Williams; Steven M Scharf
Journal:  Sleep Breath       Date:  2007-06       Impact factor: 2.655

View more
  5 in total

1.  Obstructive Sleep Apnea in Patients With Fibrotic Interstitial Lung Disease and COPD.

Authors:  Xiao Lei Zhang; Hua Ping Dai; Hui Zhang; Bo Gao; Li Zhang; Teng Han; Chen Wang
Journal:  J Clin Sleep Med       Date:  2019-10-26       Impact factor: 4.062

2.  Alpha-1 Adrenergic-Antagonist Use Increases the Risk of Sleep Apnea: A Nationwide Population-Based Cohort Study.

Authors:  Po-Lan Su; Wen-Kuei Lin; Cheng-Yu Lin; Sheng-Hsiang Lin
Journal:  J Clin Sleep Med       Date:  2019-11-15       Impact factor: 4.062

3.  Self-reported sleep quality and acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Jeanne Geiger-Brown; Sarah Lindberg; Samuel Krachman; Charlene E McEvoy; Gerard J Criner; John E Connett; Richard K Albert; Steven M Scharf
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-02-20

4.  Fatigue and sleepiness determine respiratory quality of life among veterans evaluated for sleep apnea.

Authors:  Denis Vinnikov; Paul D Blanc; Alaena Alilin; Moshe Zutler; Jon-Erik C Holty
Journal:  Health Qual Life Outcomes       Date:  2017-03-14       Impact factor: 3.186

5.  Obstructive sleep apnoea in patients with fibrotic diffuse parenchymal lung disease-characterization and treatment compliance assessment.

Authors:  Ana Verónica Cardoso; Nuno Pereira; Inês Neves; Vanessa Santos; José Miguel Jesus; Natália Melo; Patrícia Caetano Mota; António Morais; Marta Drummond
Journal:  Can J Respir Ther       Date:  2018-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.